The recently introduced Aedes albopictus in Tunisia has the potential to transmit chikungunya, dengue and Zika viruses

PLoS Negl Trop Dis. 2020 Oct 2;14(10):e0008475. doi: 10.1371/journal.pntd.0008475. eCollection 2020 Oct.

Abstract

The mosquito Aedes albopictus was detected for the first time in Tunisia in 2018. With its establishment in the capital city of Tunis, local health authorities fear the introduction of new human arboviral diseases, like what happened in Europe with unexpected local cases of chikungunya, dengue and Zika. Even though this mosquito is competent to transmit the arboviruses mentioned above, the transmission level will vary depending on the couple, mosquito population and virus genotype. Here, we assessed the vector competence of Ae. albopictus Tunisia by experimental infections with chikungunya (CHIKV), dengue (DENV), and Zika (ZIKV) viruses. We found that Ae. albopictus Tunisia was highly competent for CHIKV (transmission efficiency of 25% at 21 post-infection) and to a lesser extent, for ZIKV (8.7%) and DENV (8.3%). Virus was detected in mosquito saliva at day 3 (CHIKV), day 10 (ZIKV) and day 21 (DENV) post-infection. These results suggest that the risk of emergence of chikungunya is the highest imposing a more sustained surveillance to limit Ae. albopictus populations in densely populated urban dwellings and at the entry points of travelers returning from CHIKV-endemic regions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aedes / virology*
  • Animals
  • Cell Line
  • Chikungunya Fever / transmission*
  • Chikungunya virus
  • Chlorocebus aethiops
  • Dengue / transmission*
  • Dengue Virus
  • Female
  • Male
  • Mosquito Vectors / virology*
  • Rabbits
  • Saliva / virology
  • Tunisia
  • Vero Cells
  • Zika Virus
  • Zika Virus Infection / transmission*

Grants and funding

This study was funded by the European Union's Horizon 2020 research and innovation programme under grant agreement No 731060 (Infravec2, Research Infrastructures for the control of vector-borne diseases; http://infravec2.eu/). CB was supported by the Institut Pasteur. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.